| |
| center
|
:
|
Isfahan University of Medical Sciences
|
| Document Type
|
:
|
Latin Dissertation
|
| Language of Document
|
:
|
English
|
| Record Number
|
:
|
103462
|
| Doc. No
|
:
|
T15057
|
| Call number
|
:
|
WK,820,D712e,2014
|
| Main Entry
|
:
|
Dormiani Tabatabai, Mehrnaz
|
| Title & Author
|
:
|
The effect of pioglitazone on circulating interleukin-10 and tumour necrosis factor-alpha levels in patient with metabolic syndrome: a randomized, double-blind controlled trial/مهرناز درمیانی طباطبایی
|
| College
|
:
|
Schools, Medical
|
| Date
|
:
|
, 2014
|
| Degree
|
:
|
Cardiology, Speciality
|
| Page No
|
:
|
[15] p.: tab.
|
| Note
|
:
|
This thesis is a research project with project ID: 393231
|
| Abstract
|
:
|
Background: This study aimed to evaluate the effect of pioglitazone as an insulin sensitizer on circulating interleukin-10 (IL-10) as an anti-inflammatory factor and tumour necrosis factor-alpha (TNF-alfa) as main pre-inflammatory factor in nondiabetic metabolic syndrome (MetS) patients in Caucasians race of Middle East area in Iran. Methods: We conducted a randomized double-blind controlled study of 68 nondiabetic patients with MetS. Patients were randomly divided into two groups including intervention group received pioglitazone 30 mg daily for 24 weeks and the control group received placebo pills for the same duration. Circulating levels of TNF-alfa and IL-10 were assessed as a primary goal. Lipid profile, liver enzymes, blood pressure, waist circumference and body mass index (BMI) also were measured.Results: Lipid profile had non-significant changes after treatment by pioglitazone, but BMI was increased significantly (P = 0.002). Blood pressure and waist circumference had significant decrease in both groups (P < 0.050). Aspartate transaminase and alanine transaminase were decreased significantly in pioglitazone group (P = 0.002). TNF-alfa decreased non-significantly in both groups (P > 0.050). IL-10 increased in intervention group non-significantly (P = 0.971); while in placebo group decreased to a little extent (P = 0.401). C-reactive protein was also decreased insignificant after receive pioglitazone (P = 0.333). There was no significant difference in all variables between the two groups (P > 0.050). Conclusion: This study indicates that pioglitazone has no positive effect on improving inflammatory status in the non-diabetes patients with MetS.
|
| Descriptor
|
:
|
1.Metabolic Syndrome X.- Descriptors: Metabolic Syndrome X
|
|
|
:
|
pioglitazone
|
|
|
:
|
Interleukins
|
| Added Entry
|
:
|
Sadeghi, Masoumeh, Supervisor
|
|
|
:
|
Pourmoghadas, Ali, Supervisor
|
| Translated Title Supplied by Cataloguer
|
:
|
بررسی اثر پیوگلیتازون بر سطح سرمی اینترلوکین ۱۰ و TNFa در بیماران مبتلا به سندرم متابولیک
|
| | | | | |
| | |  |
http://elib.mui.ac.ir/site/catalogue/103462
| | | |
| | | |
|